Risk of a first-ever acute myocardial infarction and all-cause mortality with sulphonylurea treatment: A population-based cohort study

Judith van Dalem, Martijn C. G. J. Brouwers, Coen D. A. Stehouwer, Andre Krings, Olaf H. Klungel, Johanna H. M. Driessen, Frank de Vries*, Andrea M. Burden

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)1056-1060
Number of pages5
JournalDiabetes Obesity & Metabolism
Volume20
Issue number4
DOIs
Publication statusPublished - Apr 2018

Keywords

  • acute myocardial infarction
  • all-cause mortality
  • sulphonylureas
  • type 2 diabetes mellitus
  • CARDIOVASCULAR SAFETY
  • SEVERE HYPOGLYCEMIA
  • METAANALYSIS
  • EVENTS
  • ASSOCIATION
  • MONOTHERAPY
  • METFORMIN
  • OUTCOMES
  • USERS
  • DEATH
  • Humans
  • Middle Aged
  • Male
  • Cause of Death
  • Young Adult
  • Sulfonylurea Compounds/adverse effects
  • Aged, 80 and over
  • Adult
  • Female
  • Risk Factors
  • Myocardial Infarction/chemically induced
  • United Kingdom/epidemiology
  • Diabetes Mellitus, Type 2/drug therapy
  • Adolescent
  • Survival Analysis
  • Aged
  • Hypoglycemic Agents/adverse effects
  • Cohort Studies

Cite this